Targeting NF-κB for colorectal cancer

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-49
   PubMed Web of Science ®Google Scholar
• Chu QS, Hammond LA, Schwartz G, Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies. Clin Cancer Res 2004;10(15):4913-21
   PubMedGoogle Scholar
• Tournigand C, Andre T, Achille E, FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22(2):229-37
   PubMed Web of Science ®Google Scholar
• Arsene D, Galais MP, Bouhier-Leporrier K, Reimund JM. Recent developments in colorectal cancer treatment by monoclonal antibodies. Expert Opin Biol Ther 2006;6(11):1175-92
   PubMedGoogle Scholar
• Fakih M. Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach? Expert Rev Anticancer Ther 2008;8(9):1471-80
   PubMedGoogle Scholar
• Prat A, Casado E, Cortes J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007;13(44):5857-66
   PubMedGoogle Scholar
• Rodriguez J, Zarate R, Bandres E, Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007;13(44):5867-76
   PubMedGoogle Scholar
• Kamata H, Honda S, Maeda S, Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005;120(5):649-61
   PubMed Web of Science ®Google Scholar
• Maeda S, Omata M. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci 2008;99(5):836-42
   PubMedGoogle Scholar
• Clevers H. At the crossroads of inflammation and cancer. Cell 2004;118(6):671-4
   PubMedGoogle Scholar
• Karin M, Cao Y, Greten FR, Li ZW. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002;2(4):301-10
   PubMedGoogle Scholar
• Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109(Suppl):S81-96
   PubMedGoogle Scholar
• van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 2005;54(11):1573-8
   PubMedGoogle Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48(4):526-35
   PubMedGoogle Scholar
• Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91(4):854-62
   PubMedGoogle Scholar
• Atreya I, Atreya R, Neurath MF. NF-κB in inflammatory bowel disease. J Intern Med 2008;263(6):591-6
   PubMedGoogle Scholar
• Neurath MF, Pettersson S, Meyer zum Buschenfelde KH, Strober W. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-κB abrogates established experimental colitis in mice. Nat Med 1996;2(9):998-1004
   PubMedGoogle Scholar
• Rogler G, Brand K, Vogl D, Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998;115(2):357-69
   PubMedGoogle Scholar
• Neurath MF, Fuss I, Schurmann G, Cytokine gene transcription by NF-κB family members in patients with inflammatory bowel disease. Ann NY Acad Sci 1998;859:149-59
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002;347(6):417-29
   PubMedGoogle Scholar
• Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl 2):1-5
   PubMedGoogle Scholar
• Yan F, Polk DB. Aminosalicylic acid inhibits IκB kinase alpha phosphorylation of IκBalpha in mouse intestinal epithelial cells. J Biol Chem 1999;274(51):36631-6
   PubMedGoogle Scholar
• Greten FR, Eckmann L, Greten TF, IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118(3):285-96
   PubMed Web of Science ®Google Scholar
• Becker C, Fantini MC, Schramm C, TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004;21(4):491-501
   PubMedGoogle Scholar
• Shibata W, Maeda S, Hikiba Y, Cutting edge: the IκB kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks inflammatory injury in murine colitis. J Immunol 2007;179(5):2681-5
   PubMedGoogle Scholar
• Hayakawa Y, Maeda S, Nakagawa H, Effectiveness of IκB kinase inhibitors in murine colitis-associated tumorigenesis. J Gastroenterol 2009;44(9):935-43
   PubMedGoogle Scholar
• Rajagopalan H, Nowak MA, Vogelstein B, Lengauer C. The significance of unstable chromosomes in colorectal cancer. Nat Rev Cancer 2003;3(9):695-701
   PubMedGoogle Scholar
• Arends JW. Molecular interactions in the Vogelstein model of colorectal carcinoma. J Pathol 2000;190(4):412-6
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70
   PubMed Web of Science ®Google Scholar
• Joyce D, Albanese C, Steer J, NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001;12(1):73-90
   PubMedGoogle Scholar
• Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002;13(4-5):413-21
   PubMedGoogle Scholar
• Goldring MB, Otero M, Tsuchimochi K, Defining the roles of inflammatory and anabolic cytokines in cartilage metabolism. Ann Rheum Dis 2008;67(Suppl 3):75-82
   Google Scholar
• Chen F, Lu Y, Castranova V, Loss of Ikkbeta promotes migration and proliferation of mouse embryo fibroblast cells. J Biol Chem 2006;281(48):37142-9
   PubMedGoogle Scholar
• Luo JL, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death–a new approach to cancer therapy. J Clin Invest 2005;115(10):2625-32
   PubMedGoogle Scholar
• De Smaele E, Zazzeroni F, Papa S, Induction of gadd45beta by NF-κB downregulates pro-apoptotic JNK signalling. Nature 2001;414(6861):308-13
   PubMedGoogle Scholar
• Muerkoster S, Arlt A, Sipos B, Increased expression of the E3-ubiquitin ligase receptor subunit beta TRCP1 relates to constitutive nuclear factor-κB activation and chemoresistance in pancreatic carcinoma cells. Cancer Res 2005;65(4):1316-24
   PubMedGoogle Scholar
• Cheng Q, Lee HH, Li Y, Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibition. Oncogene 2000;19(42):4936-40
   PubMedGoogle Scholar
• Kunnumakkara AB, Guha S, Krishnan S, Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products. Cancer Res 2007;67(8):3853-61
   PubMedGoogle Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2(3):161-74
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009;28(1-2):15-33
   PubMedGoogle Scholar
• Huber MA, Azoitei N, Baumann B, NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004;114(4):569-81
   PubMedGoogle Scholar
• Wu Y, Deng J, Rychahou PG, Stabilization of snail by NF-κB is required for inflammation-induced cell migration and invasion. Cancer Cell 2009;15(5):416-28
   PubMedGoogle Scholar
• Kim S, Takahashi H, Lin WW, Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009;457(7225):102-6
   PubMedGoogle Scholar
• Maeda S, Hikiba Y, Sakamoto K, Iκ B kinasebeta/nuclear factor-κB activation controls the development of liver metastasis by way of interleukin-6 expression. Hepatology 2009;50(6):1851-60
   PubMedGoogle Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Shishodia S, Sandur SK, Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72(11):1605-21
   PubMedGoogle Scholar
• Sakamoto K, Maeda S, Hikiba Y, Constitutive NF-κB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 2009;15(7):2248-58
   PubMed Web of Science ®Google Scholar
• Bates RC, DeLeo MJ III, Mercurio AM. The epithelial-mesenchymal transition of colon carcinoma involves expression of IL-8 and CXCR-1-mediated chemotaxis. Exp Cell Res 2004;299(2):315-24
   PubMedGoogle Scholar
• Wang B, Hendricks DT, Wamunyokoli F, Parker MI. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 2006;66(6):3071-7
   PubMedGoogle Scholar
• Wang D, Richmond A. Nuclear factor-κB activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J Biol Chem 2001;276(5):3650-9
   PubMedGoogle Scholar
• Ma J, Wang Q, Fei T, MCP-1 mediates TGF-beta-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 2007;109(3):987-94
   PubMedGoogle Scholar
• Singh S, Sadanandam A, Singh RK. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007;26(3-4):453-67
   PubMedGoogle Scholar
• Scapini P, Morini M, Tecchio C, CXCL1/macrophage inflammatory protein-2-induced angiogenesis in vivo is mediated by neutrophil-derived vascular endothelial growth factor-A. J Immunol 2004;172(8):5034-40
   PubMedGoogle Scholar
• Voboril R, Weberova-Voborilova J. Constitutive NF-kappaB activity in colorectal cancer cells: impact on radiation-induced NF-kappaB activity, radiosensitivity, and apoptosis. Neoplasma 2006;53(6):518-23
   PubMedGoogle Scholar
• Lind DS, Hochwald SN, Malaty J, Nuclear factor-κB is upregulated in colorectal cancer. Surgery 2001;130(2):363-9
   PubMedGoogle Scholar
• McConkey DJ, Zhu K. Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resist Updat 2008;11(4-5):164-79
   PubMedGoogle Scholar
• Williams S, Pettaway C, Song R, Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003;2(9):835-43
   PubMedGoogle Scholar
• Nawrocki ST, Carew JS, Pino MS, Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66(7):3773-81
   PubMedGoogle Scholar
• Zhu H, Zhang L, Dong F, Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005;24(31):4993-9
   PubMedGoogle Scholar
• Caponigro F, Lacombe D, Twelves C, An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. Eur J Cancer 2009;45(1):48-55
   PubMedGoogle Scholar
• San Miguel J, Blade J, Boccadoro M, A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006;11(1):51-61
   PubMedGoogle Scholar
• Raab MS, Podar K, Breitkreutz I, Multiple myeloma. Lancet 2009;374(9686):324-39
   PubMed Web of Science ®Google Scholar
• Jin SH, Kim TI, Han DS, Thalidomide suppresses the interleukin 1beta-induced NFκB signaling pathway in colon cancer cells. Ann NY Acad Sci 2002;973:414-8
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113(9):1875-91
   PubMedGoogle Scholar
• Yu J, Qian H, Li Y, Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. Gynecol Oncol 2007;106(2):400-6
   PubMedGoogle Scholar
• Subbarayan PR, Lima M, Ardalan B. Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol 2007;46(4):557-61
   PubMedGoogle Scholar
• Epinat JC, Gilmore TD. Diverse agents act at multiple levels to inhibit the Rel/NF-κB signal transduction pathway. Oncogene 1999;18(49):6896-909
   PubMedGoogle Scholar
• Saklatvala J. Glucocorticoids: do we know how they work? Arthritis Res 2002;4(3):146-50
   PubMedGoogle Scholar
• Almawi WY, Melemedjian OK. Negative regulation of nuclear factor-κB activation and function by glucocorticoids. J Mol Endocrinol 2002;28(2):69-78
   PubMedGoogle Scholar
• Kemeny N, Capanu M, D'Angelica M, Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol 2009;20(7):1236-41
   PubMedGoogle Scholar
• Sakimura K, Omori T, Iwashita E, Clinical response is associated with elevated plasma interleukin-1 receptor antagonist during selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006;51(9):1525-31
   PubMedGoogle Scholar
• Graziano F, Ruzzo A, Canestrari E, Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. Pharmacogenomics J 2009;9(1):78-84
   PubMedGoogle Scholar
• Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3(1):17-26
   PubMed Web of Science ®Google Scholar
• You M, Ku PT, Hrdlickova R, Bose HR Jr. ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol Cell Biol 1997;17(12):7328-41
   PubMedGoogle Scholar
• Stehlik C, de Martin R, Kumabashiri I, Nuclear factor (NF)-κB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 1998;188(1):211-6
   PubMedGoogle Scholar
• Stehlik C, de Martin R, Binder BR, Lipp J. Cytokine induced expression of porcine inhibitor of apoptosis protein (iap) family member is regulated by NF-κB. Biochem Biophys Res Commun 1998;243(3):827-32
   PubMedGoogle Scholar
• Roy N, Deveraux QL, Takahashi R, The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 1997;16(23):6914-25
   PubMedGoogle Scholar
• Varfolomeev E, Blankenship JW, Wayson SM, IAP antagonists induce autoubiquitination of c-IAPs, NF-κB activation, and TNFalpha-dependent apoptosis. Cell 2007;131(4):669-81
   PubMed Web of Science ®Google Scholar
• Malinin NL, Boldin MP, Kovalenko AV, Wallach D. MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 1997;385:540-4
   PubMed Web of Science ®Google Scholar
• Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-κB activation pathways by NF-B-inducing kinase. Immunity 2004;21(4):477-89
   PubMedGoogle Scholar